University of North Carolina School of Medicine Jul 3 2025 Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a stalwart for HIV prevention-but only if people take it consistently and can routinely access a pharmacy. In 2022, Gilead Sciences, Inc., received U.S. Food and Drug Administration (FDA) approval for lenacapavir, a twice-yearly injectable medication